Article Text

other Versions

Download PDFPDF
Randomised controlled trial
Prolonged dual antiplatelet therapy after drug-eluting stent reduces the risk of stent thrombosis and major cardiovascular events but increases the rate of bleeding
  1. Gérard Helft
  1. Institut de Cardiologie, Pitié-Salpétrière, AP-HP, Paris VI University, Paris, France
  1. Correspondence to : Dr Gérard Helft, Institut de Cardiologie, Pitié-Salpétrière, AP-HP, Paris VI University, 75013 Paris, France; gerard.helft{at}

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Commentary on: OpenUrlCrossRefPubMedWeb of Science


The implantation of drug-eluting stents (DES) has become a standard treatment for the management of patients with coronary artery disease. The use of dual antiplatelet therapy (DAPT) is critically important for the prevention of coronary stent thrombosis. Current clinical guidelines recommend at least 6–12 months of treatment after DES implantation; however, a longer duration of DAPT may be beneficial.1


This study is an international, randomised, placebo-controlled trial that was designed to determine the benefits and risks of continuing DAPT beyond …

View Full Text


  • Competing interests None.

  • Provenance and peer review Commissioned; internally peer reviewed.